[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"biomarker:carcinoembryonic-antigen":3},{"name":4,"total":5,"recruiting":6,"trials":7},"Carcinoembryonic Antigen",5,4,[8,16,23,29,35],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT06130826","Immune Response Activation for the Treatment of Unresectable Metastatic Colorectal Cancer or CEA Positive Metastatic Breast Cancer",[12],"Phase 1","RECRUITING","2026-08-26T02:17:05.172421Z","2026-05-05T02:43:29.534208Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT05415709","Hyperthermic Intraperitoneal Chemotherapy With Cisplatin During Surgery or Cisplatin Before Surgery for the Treatment of Stage III or IV Ovarian, Fallopian Tube or Peritoneal Cancer",[20],"Early Phase 1","2026-08-03T02:06:20.225302Z","2026-05-05T02:43:28.502526Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":27,"content_modified":28},"NCT05204147","Actinium 225 Labeled Anti-CEA Antibody (Ac225-DOTA-M5A) for the Treatment of CEA Producing Advanced or Metastatic Cancers",[12],"2026-08-26T02:17:06.985283Z","2026-07-19T19:36:05.131963Z",{"nct_id":30,"title":31,"phases":32,"status":13,"updated_at":33,"content_modified":34},"NCT03723928","S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer",[],"2026-08-26T02:19:26.493949Z","2026-05-05T02:43:27.740859Z",{"nct_id":36,"title":37,"phases":38,"status":39,"updated_at":40,"content_modified":41},"NCT05245786","An Investigational Scan (64Cu-Labeled M5A Antibody) in Combination With SOC Chemotherapy and Radiotherapy in Locally Advanced Rectal Cancer",[20],"ACTIVE_NOT_RECRUITING","2026-08-03T02:02:00.894089Z","2026-05-05T02:43:26.740176Z"]